Eskisehir Osmangazi University, abbreviated as ESOGU, is located in Eskişehir, in the Eskişehir Province of Turkey.

During the past decade, Eskisehir Osmangazi University Medical Faculty conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 6 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 5 clinical trials were completed. i.e. 35.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Eskisehir Osmangazi University Medical Faculty" #1 sponsor was "Bayer" with 4 trials, followed by "Abbott Nutrition" with 2 trials sponsored, "Camurus AB" with 2 trials sponsored, "Diskapi Teaching and Research Hospital" with 2 trials sponsored and "Eskisehir Osmangazi University" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Eskisehir Osmangazi University Medical Faculty" #1 collaborator was "Klinar CRO" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Turkish Neurological Society" with 2 trials as a collaborator, "Abbott Nutrition" with 1 trials as a collaborator and "ElectroCore INC" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Eskisehir Osmangazi University Medical Faculty" are "Acromegaly" (2 trials), "Blood Transfusion" (2 trials), "Heart Failure" (2 trials), "Retinopathy of Prematurity (ROP)" (2 trials) and "Stroke" (2 trials). Many other conditions were trialed in "Eskisehir Osmangazi University Medical Faculty" in a lesser frequency.

Most popular intervention types in "Eskisehir Osmangazi University Medical Faculty" are "Drug" (13 trials), "Other" (5 trials), "Procedure" (3 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Blood transfusion" (2 trials), "CAM2029 (octreotide subcutaneous depot)" (2 trials), "Ceftolozane/Tazobactam" (2 trials) and "Eylea (Aflibercept, BAY86-5321)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Eskisehir Osmangazi University Medical Faculty" are 23 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Eskisehir Osmangazi University Medical Faculty". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Eskisehir Osmangazi University Medical Faculty, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Eskisehir Osmangazi University Medical Faculty, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".